Hengrui Pharmaceutical announced that the subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS - 8797 tablets and will conduct clinical trials for atopic dermatitis in the near future. This drug is a Class 1 innovative drug independently developed by the company. No similar drug has been approved for marketing in the world, and the total R&D investment for related projects is about 32.9 million yuan. The drug development and marketing cycle is long, there are many steps, and there is uncertainty. The company will advance the project and disclose the progress in a timely manner.

Hengrui Pharmaceutical announced that the subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS - 8797 tablets and will conduct clinical trials for atopic dermatitis in the near future. This drug is a Class 1 innovative drug independently developed by the company. No similar drug has been approved for marketing worldwide, and the total R&D investment for related projects is about 32.9 million yuan. The drug development and marketing cycle is long, there are many steps, and there is uncertainty. The company will advance the project and disclose the progress in a timely manner.